Pamela Zeitlin is a Respiratory physician affiliated with National Jewish Health. OpenAlex indexes 196 publications with 12,078 citations (h-index 56); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Pediatric Pulmonology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1400 Jackson St
Denver, CO 802062761
Telephone
303-388-4461Provider last certified this registry record 17 Mar 2021.
Clinical trials
- Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)
Sponsor: National Jewish Health
- Phase II Study of Digitoxin to Treat Cystic Fibrosis
Sponsor: National Jewish Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year20241 payment
- Vertex Pharmaceuticals IncorporatedProgram year20231 payment
- Vertex Pharmaceuticals IncorporatedProgram year20225 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2016–2022 per NIH RePORTER. The latest:
- Mechanism of Prostone Activation During CFTR Modulation
National Jewish Health
FY2022$426,793R56HL157318 - Ph 1-2 Study of Glycerolphenylbutyrate for Cystic Fibrosis IND 125,124 (12/5/15)
National Jewish Health
FY2019$125,000R01FD005380 - Ph 1-2 Study of Glycerolphenylbutyrate for Cystic Fibrosis IND 125,124 (12/5/15)
National Jewish Health
FY2016$230,476R01FD005380
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Airway microbiota across age and disease spectrum in cystic fibrosis
European Respiratory Journal
2017 - Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
The Lancet Respiratory Medicine
2014
Similar KOLs
Other experts from the same institution or the same specialty.
James Crapo, MD
National Jewish Health
Barry Make, MD
National Jewish Health
Jeffrey Swigris, DO
National Jewish Health
Michael Wechsler, MD
National Jewish Health
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Marshall University
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”